CO5021199A1 - DERIVATIVES OF 8-PHENYLXANTINE - Google Patents
DERIVATIVES OF 8-PHENYLXANTINEInfo
- Publication number
- CO5021199A1 CO5021199A1 CO99034567A CO99034567A CO5021199A1 CO 5021199 A1 CO5021199 A1 CO 5021199A1 CO 99034567 A CO99034567 A CO 99034567A CO 99034567 A CO99034567 A CO 99034567A CO 5021199 A1 CO5021199 A1 CO 5021199A1
- Authority
- CO
- Colombia
- Prior art keywords
- mono
- alkylamino
- groups
- group
- hydroxy
- Prior art date
Links
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- -1 hydroxy, carbamoyl Chemical group 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 3
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Chemical group 0.000 abstract 2
- 229910052717 sulfur Chemical group 0.000 abstract 2
- 239000011593 sulfur Chemical group 0.000 abstract 2
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Surgery (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Un compuesto de la fórmula (I)En donde:R1 , R2 y R3 representan cada una independientemente un átomo de hidrógeno o un grupo alquenilo, alquinilo, cicloalquilo o alquilcarbomoilo o un grupo alquilo que puede estar no sustituido o sustituido por 1 o más átomos de halógeno o grupos hidroxi, alcoxilo, cicloalquilo, alquiltio, amino, mono- o dialquilamino, cicloalquilo, oxo, hidroxicarbonilo, alcoxicarbonilo, carbamoilo o alquilcarbamoilo, o un grupo benzilo o fenilo que puede estar sustituido o no sustituido por uno o más átomos halógenos o grupos alquilo, hidroxi, alquilenedioxi, alcoxi, amino, mono- o di- alquilamino, nitro, ciano o trifluorometil; Cualquiera R4 y R5 juntos con el átomo de nitrógeno al cual están ligados forman un anillo de 3 a 7 miembros que comprende un total entre 1 a 4 heteroátomos seleccionados a partir de nitrógeno, oxígeno, y azufre, dicho anillo puede ser sustituido o no sustituido por 1 o 2 átomos de halógeno o grupos hidroxi, carbamoilo, hidroxicarbonilo, alcoxicarbonilo, amino, mono- o di alquilamino o 1 o 2 grupos alquilo que pueden estar sustituidos o no sustituidos por 1 o más grupos hidroxi, alcoxi, hidroxialcoxi, hidroxicarbonilo, alcoxicarbonilo, amino o mono- o di alquilamino, oR4 es como se definió para R1 y R5 que se presenta un grupo alquenilo, alquinilo, cicloalquilo, mono- o di- alquilamino, alquilcarbamoilo, aminocarboiminoilo o un grupo alquilo sustituido por uno o más átomos halógeno o un grupo hidroxi, alcoxi, cicloalquilo, alquiltio, oxo, hidroxicarbonilo, alcoxicarbonilo, carbamoilo, alquilcarbamoilo, amino o mono- di- alquilamino, o R5 representa un grupo de la fórmula -(CH2 )n -R7 En donde n es un número que va de 0 a 4 y R1 representa un anillo de 3 a 7 miembros que comprende de 1 a 4 heteroátomos seleccionados a partir de nitrógeno, oxígeno y azufre, dicho anillo puede ser sustituido o no sustituido por uno o más átomos halógeno o grupos hidroxi, fenilo, alcoxicarbonilo, amino, mono-alquilamino, di-alquilamino o hidroxicarbonilo o uno o más grupos alquilo que pueden estar sustituidos por uno o más átomos halógenos o grupos hidroxi, fenilo, alcoxicarbonilo, amino, mono- o di- alquilamino o grupos hidroxicarbonilo;R6 representa un átomo de hidrógeno o un grupo alquilo; Y el grupo -SO2 NR4 R5 está en las posiciones 4 o 5 sobre el grupo fenilo;O una sal farmacéuticamente aceptable de lo anterior.A compound of the formula (I) wherein: R1, R2 and R3 each independently represent a hydrogen atom or an alkenyl, alkynyl, cycloalkyl or alkylcarbomoyl group or an alkyl group that may be unsubstituted or substituted by 1 or more atoms of halogen or hydroxy, alkoxy, cycloalkyl, alkylthio, amino, mono- or dialkylamino, cycloalkyl, oxo, hydroxycarbonyl, alkoxycarbonyl, carbamoyl or alkylcarbamoyl groups, or a benzyl or phenyl group which may be substituted or unsubstituted by one or more halogen atoms or alkyl, hydroxy, alkylenedioxy, alkoxy, amino, mono- or di-alkylamino, nitro, cyano or trifluoromethyl groups; Any R4 and R5 together with the nitrogen atom to which they are bound form a 3 to 7 member ring comprising a total of 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur, said ring can be substituted or unsubstituted by 1 or 2 halogen atoms or hydroxy, carbamoyl, hydroxycarbonyl, alkoxycarbonyl, amino, mono- or di-alkylamino groups or 1 or 2 alkyl groups which may be substituted or unsubstituted by 1 or more hydroxy, alkoxy, hydroxyalkoxy, hydroxycarbonyl groups, alkoxycarbonyl, amino or mono- or di-alkylamino, or R4 is as defined for R1 and R5 which presents an alkenyl, alkynyl, cycloalkyl, mono- or di-alkylamino, alkylcarbamoyl, aminocarboiminoyl group or an alkyl group substituted by one or more atoms halogen or a hydroxy, alkoxy, cycloalkyl, alkylthio, oxo, hydroxycarbonyl, alkoxycarbonyl, carbamoyl, alkylcarbamoyl, amino or mono-di-alkylamino group, or R5 represents a group of the formula - (CH2) n -R7 Where n is a number ranging from 0 to 4 and R1 represents a 3 to 7 member ring comprising 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, said ring can be substituted or unsubstituted by one or more halogen atoms or hydroxy, phenyl, alkoxycarbonyl, amino, mono-alkylamino, di-alkylamino or hydroxycarbonyl groups or one or more alkyl groups which may be substituted by one or more halogen atoms or hydroxy groups, phenyl , alkoxycarbonyl, amino, mono- or di-alkylamino or hydroxycarbonyl groups: R 6 represents a hydrogen atom or an alkyl group; And the group -SO2 NR4 R5 is in positions 4 or 5 on the phenyl group; or a pharmaceutically acceptable salt of the above.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES9801152 | 1998-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5021199A1 true CO5021199A1 (en) | 2001-03-27 |
Family
ID=8304000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO99034567A CO5021199A1 (en) | 1998-06-03 | 1999-06-02 | DERIVATIVES OF 8-PHENYLXANTINE |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR018619A1 (en) |
| AU (1) | AU4501199A (en) |
| CO (1) | CO5021199A1 (en) |
| PE (1) | PE20000557A1 (en) |
| WO (1) | WO1999062905A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2166270B1 (en) * | 1999-07-27 | 2003-04-01 | Almirall Prodesfarma Sa | DERIVATIVES OF 8-PHENYL-6,9-DIHIDRO- (1,2,4,) TRIAZOLO (3,4-I) PURIN-5-ONA. |
| GB0007934D0 (en) * | 2000-03-31 | 2000-05-17 | Darwin Discovery Ltd | Chemical compounds |
| US7019136B2 (en) | 2000-04-07 | 2006-03-28 | Novartis, Ag | 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors |
| US6919337B2 (en) | 2000-04-07 | 2005-07-19 | Novartis, Ag | 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors |
| GB0008694D0 (en) * | 2000-04-07 | 2000-05-31 | Novartis Ag | Organic compounds |
| CA2411013A1 (en) * | 2000-06-07 | 2001-12-13 | Jose Manuel Prieto Soto | 6-phenylpyrrolopyrimidinedione derivatives |
| CA2417784A1 (en) * | 2000-08-09 | 2002-02-14 | Almirall Prodesfarma S.A. | Pyrrolotriazolopyrimidinone derivatives |
| US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
| CN1127506C (en) * | 2001-06-29 | 2003-11-12 | 刘宝顺 | Compound for treating impotence |
| EP1421084B1 (en) | 2001-08-28 | 2008-05-14 | Schering Corporation | Polycyclic guanine phosphodiesterase v inhibitors |
| WO2003042216A1 (en) | 2001-11-09 | 2003-05-22 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase v inhibitors |
| US11666888B2 (en) | 2018-02-05 | 2023-06-06 | Bio-Rad Laboratories, Inc. | Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3347290A1 (en) * | 1983-12-28 | 1985-07-11 | Dr. Karl Thomae Gmbh, 7950 Biberach | NEW 2-PHENYL IMIDAZOLES, THEIR PRODUCTION AND MEDICINES CONTAINING THESE COMPOUNDS |
| GB8817651D0 (en) * | 1988-07-25 | 1988-09-01 | Smith Kline French Lab | Chemical compounds |
| GB9213623D0 (en) * | 1992-06-26 | 1992-08-12 | Pfizer Ltd | Therapeutic agents |
-
1999
- 1999-05-26 WO PCT/EP1999/003644 patent/WO1999062905A1/en not_active Ceased
- 1999-05-26 AU AU45011/99A patent/AU4501199A/en not_active Abandoned
- 1999-05-31 PE PE1999000459A patent/PE20000557A1/en not_active Application Discontinuation
- 1999-06-02 AR ARP990102608A patent/AR018619A1/en unknown
- 1999-06-02 CO CO99034567A patent/CO5021199A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR018619A1 (en) | 2001-11-28 |
| AU4501199A (en) | 1999-12-20 |
| WO1999062905A1 (en) | 1999-12-09 |
| PE20000557A1 (en) | 2000-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5190717A1 (en) | DERIVATIVES OF 8-PHENYL-6.9 DIHIDRO- [1,2,4] TRIAZOL [3,4, I] PURIN-5-ONA | |
| CO5021199A1 (en) | DERIVATIVES OF 8-PHENYLXANTINE | |
| ES2213007T3 (en) | DERIVATIVES OF 4,5-DIARIL-3 (2H) -FURANONE AS INHIBITORS OF CYCLLOXYGENASA-2. | |
| AR048669A1 (en) | BISAMIDE BICYCLE DERIVATIVES | |
| BR0201697A (en) | Alpha-amino acid compounds, process for their preparation and pharmaceutical compositions containing them | |
| AR032453A1 (en) | DERIVADOS ALQUINIL FENIL HETEROAROMATICOS ACTIVADORES DE GLUCOQUINASA, A PROCESS FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS, THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF MEDICINES | |
| AR040076A1 (en) | DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA | |
| AR029301A1 (en) | COMPOUNDS DERIVED FROM BIARILO, METHODS FOR THEIR PREPARATION COMPOSITIONS THAT CONTAIN THEM, THEIR USE AS AGONISTS IN BETA-ADRENO-ATIPIC RECEIVERS | |
| AR065937A2 (en) | INDAZOL DERIVATIVE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE IN THE MANUFACTURE OF MEDICINES TO MODULATE THE ACTIVITY OF PROTEIN KINASE | |
| MXPA02011844A (en) | Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds. | |
| AR036107A1 (en) | DERIVATIVES OF 6-PHENYLPIRROLPIRIMIDINDIONA, ANTAGONIST OF ADENOSINE A2 RECEPTORS, PARTICULARLY OF SUBTIPO A2, APPLICATION IN THE PREVENTION OF THE DEGRANULATION OF MASTOCITS; PHARMACEUTICAL COMPOSITIONS FORMULATED WITH SUCH COMPOUNDS AND THE SAME USE IN THE PREPARATION OF MEDIUM | |
| MX9206847A (en) | DERIVATIVES OF INDOLPIRROLCARBAZOL, PROCESS FOR ITS PREPARATION AND MEDICATION THAT CONTAINS THEM | |
| AR048641A1 (en) | ARTH- OR HETEROARILAMIDE ORTHOSUSTITUTED COMPOUNDS USEFUL AS ANTAGO-NISTAS OF THE PROSTAGLANDINAS E2 RECEIVER; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE MANUFACTURE OF A MEDICAME | |
| ES2196772T3 (en) | AMINO CYCLES COMPOUNDS. | |
| ECSP034660A (en) | DERIVATIVES OF THE NEW QUINUCLIDINE CARBAMATE AND THE MEDICINAL COMPOSITIONS CONTAINING THEM | |
| AR035417A1 (en) | TRICYCLE DERIVATIVES OF LACTAMA AND SULTAMA, PROCESSES FOR THEIR DEVELOPMENT, DRUGS THAT CONTAIN THEM, AND THE USE OF SUCH COMPOUNDS IN THE PREPARATION OF DRUGS | |
| AR020851A2 (en) | MACROLID COMPOUNDS, COMPOSITIONS AND ITS USE FOR THE PREPARATION OF MEDICINES | |
| AR030424A1 (en) | DERIVATIVES OF 6-PHENYLPIRROL [3,2-D] PYRIMIDINE AND 6-PHENYLPIRROL [2,3-D] -PIRIMIDIN-2,4-DIONA; PROCEDURES FOR THE PREPARATION OF SUCH DERIVATIVES; INTERMEDIARY APPLICATION COMPOUNDS IN THE PREPARATION OF SUCH DERIVATIVES AND THE USE OF THEM IN THE TREATMENT OF THE HUMAN BODY AND / OR ANIMALS AND / OR | |
| AR012764A1 (en) | COMPOUNDS DERIVED FROM ERYTHROMYCIN, COMPOSITIONS CONTAINING THEM, USES AND PROCEDURES TO PREPARE THEM. | |
| PE20221586A1 (en) | HETEROCYCLIC DERIVATIVES ACTIVE AS PESTICIDES WITH SUBSTITUENTS CONTAINING SULFUR | |
| CU23162A3 (en) | ISOSORBIDA MONONITRATE DERIVATIVES AND THEIR EMPLOYMENT AS VASODILATING AGENTS WITH DECREASED TOLERANCE | |
| BR0313734A (en) | Thiophene derivatives, their preparation process and the pharmaceutical compositions containing them | |
| ES2090024T3 (en) | CEFEMO COMPOUNDS AND PROCEDURES FOR ITS PREPARATION. | |
| AR021826A1 (en) | COMPOUNDS OF 2- FENILPIRAN-4-ONA, PROCESSES TO PREPARE THEM, USE OF AN INTERMEDIATE COMPOUND IN THESE, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND USE OF SUCH COMPOUNDS AND SUCH COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT | |
| AR053453A1 (en) | SUBSTITUTED AMINOALQUIL- AND AMIDOALQUIL-BENZOPIRANO DERIVATIVES |